IMUNON Launches Rapid Phase III OVATION 3 Trial, Initiates 15% Stock Dividend

Imunon, Inc. reported promising progress in the second quarter of 2025, highlighted by significant clinical advancements and strong cost management. The company rapidly launched its pivotal Phase 3 OVATION 3 trial for IMNN-001 in newly diagnosed advanced ovarian cancer, activating three trial sites and treating the first patient within 15 weeks, well ahead of the industry average. This trial builds on the Phase 2 OVATION 2 study, which showed a 45% improvement in median overall survival, underscoring IMNN-001's potential to transform frontline ovarian cancer treatment. Financially, Imunon has reduced operating expenses substantially, with R&D costs dropping from $2.8 million to $1.2 million and a net loss improvement from $4.8 million to $2.7 million year-over-year for the quarter. The company also announced a 15% stock dividend to shareholders and secured $3 million through warrant exercises and ATM sales, demonstrating innovative financing amid a challenging environment. While optimistic about the clinical and financial outlook, Imunon acknowledges ongoing challenges in capital raising and regulatory compliance.